P183 Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study

perception of QoC compared with patients’ perception showed that patients scored the care dimension “competence” and “costs” higher and “continuity of care” lower than physicians (Table 1). Conclusions: QoC in this Italian IBD cohort is good, and well compares to previously published results in different European Countries. Physicians’ and patients’ perspectives are similar, although physicians overscore continuity of cares and underscorecompetence and costs compared to patients. The results of this study may contribute to ameliorate standards of practice in order to optimize QoC for IBD in Italy.